問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5272Cases

2018-03-01 - 2020-06-16

Phase II

Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    ABT-165

Participate Sites
3Sites

Terminated3Sites

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 2 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2017-04-01 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

  • Condition/Disease

    Ulcerative colitis

  • Test Drug

    Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2017-05-15 - 2020-04-09

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
9Sites

Terminated8Sites

洪仁宇
Kaohsiung Municipal Gangshan Hospital

未分科

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-10-15 - 2020-04-22

Phase III

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma Multiforme (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification. (Intellance1)

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
3Sites

Terminated3Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

2017-08-01 - 2023-05-31

Phase III

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax (ABT-199/GDC-0199)

Participate Sites
5Sites

Terminated4Sites

2017-12-01 - 2020-04-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Terminated5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2016-06-06 - 2022-03-10

Phase III

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
8Sites

Terminated7Sites

黃春明
China Medical University Hospital-Taipei

未分科

2017-08-24 - 2020-12-31

Phase III

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
4Sites

Terminated4Sites

1 337 338 339 340 341 528
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB